Evidence based practice in leprosy: where do we stand?

Leprosy Review

Volumn 79, Issue 4, 2008, Pages 353-357

  Van Veen, Natasja H J ^a   Richardus, Jan Hendrik ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; OFLOXACIN; RIFAMPICIN;

CLINICAL DECISION MAKING; CLINICAL RESEARCH; CLINICAL TRIAL; DIAGNOSTIC TEST; EDITORIAL; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; HUMAN; LEPROSY; NERVE INJURY; PAUCIBACILLARY LEPROSY; RISK FACTOR; SINGLE DRUG DOSE; DECISION MAKING;

DECISION MAKING; EVIDENCE-BASED MEDICINE; HUMANS; LEPROSY;

EID: 63049110597     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (38)

1. Guyatt G, Cook D, Haynes B. Evidence based medicine has come a long way. BMJ,2004; 329(7473): 990-991.
2. Dickersin K, Straus SE, Bero LA. Evidence based medicine: increasing, not dictating, choice. BMJ, 2007; 334(Suppl 1): s10.
3. Sackett DL, Rosenberg WM, Gray JA et al. Evidence based medicine: what it is and what it isn't. BMJ, 1996; 312(7023): 71-72.
4. Reilly BM. The essence of EBM. BMJ, 2004; 329(7473): 991-992.
5. Straus SE, Jones G. What has evidence based medicine done for us? BMJ, 2004; 329(7473): 987-988.
6. Levy L. The THELEP controlled clinical trials in lepromatous leprosy World Health Organization, Geneva, 1999.
7. Gupte MD. Field trials of a single dose of the combination rifampicin-ofloxacin-minocycline (ROM) for the treatment of paucibacillary leprosy. Lepr Rev, 2000; 71(Suppl): S77-S80.
8. Kroger A, Pannikar V, Htoon MT et al. International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results. Trop Med Int Health, 2008;13: 594-602
9. Saunderson P, Gebre S, Desta K et al. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev, 2000; 71: 285-308.
10. Meima A, Saunderson PR, Gebre S et al. Factors associated with impairments in new leprosy patients: the AMFES cohort. Lepr Rev, 1999; 70: 189-203.
11. Saunderson P, Gebre S, Byass P. ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia: incidence and risk factors. Lepr Rev, 2000; 71: 318-324.
12. Meima A, Saunderson PR, Gebre S et al. Dynamics of impairment during and after treatment: the AMFES cohort. Lepr Rev, 2001; 72: 158-170.
13. Croft RP, Richardus JH, Nicholls PG, Smith WC. Nerve function impairment in leprosy: design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Lepr Rev, 1999; 70: 140-159.
14. Nicholls PG, Croft RP, Richardus JH et al. Delay in presentation, an indicator for nerve function status at registration and for treatment outcome-the experience of the Bangladesh Acute Nerve Damage Study cohort. Lepr Rev, 2003; 74: 349-356.
15. Richardus JH, Nicholls PG, Croft RP et al. Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up. Int J Epidemiol, 2004; 33: 337-343.
16. Croft RP, Nicholls PG, Steyerberg EW et al. A clinical prediction rule for nerve-function impairment in leprosy patients. Lancet, 2000; 355(9215): 1603-1606.
17. Schuring RP, Richardus JH, Steyerberg EW et al. Preventing nerve function impairment in leprosy: validation and updating of a prediction rule. PLoS Negl Trop Dis, 2008; 2: e283.
18. Smith WC, Anderson AM, Withington SG et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ, 2004; 328(7454): 1459.
19. Van Brakel WH, Anderson AM, Withington SG et al. The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Lepr Rev, 2003; 74: 300-310.
20. Richardus JH, Withington SG, Anderson AM et al. Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3). Lepr Rev, 2003; 74: 311-318.
21. van Brakel WH, Nicholls PG, Das L et al. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev, 2005; 76: 14-34.
22. van Brakel WH, Nicholls PG, Wilder-Smith EP et al. Early diagnosis of neuropathy in leprosy-comparing diagnostic tests in a large prospective study (the INFIR Cohort Study). PLoS Negl Trop Dis, 2008; 2: e212.
23. Marlowe SN, Hawksworth RA, Butlin CR et al. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Trans R Soc Trop Med Hyg, 2004; 98: 602-609.
24. Noordeen SK. Prophylaxis-scope and limitations. Lepr Rev, 2000; 71(Suppl): S16-S19; Discussion S9-20.
25. Diletto C, Blanc L, Levy L. Leprosy chemoprophylaxis in Micronesia. Lepr Rev, 2000; 71(Suppl): S21-S23; Discussion S4-5.
26. Moet FJ, Oskam L, Faber R et al. A study on transmission and a trial of chemoprophylaxis in contacts of leprosy patients: design, methodology and recruitment findings of COLEP. Lepr Rev, 2004; 75: 376-388.
27. Moet FJ, Pahan D, Oskam L et al. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ, 2008; 336(7647): 761-764.
28. Van Veen NH, Nicholls PG, Smith WC, Richardus JH. Corticosteroids for treating nerve damage in leprosy. Cochrane Database Syst Rev, 2007; : CD005491.
29. van Veen NHJ, Schreuders TAR, Theuvenet WJ, et al. Decompressive surgery for treating nerve damage in leprosy. Cochrane Database Syst Rev (accepted).
30. van Veen NHJ, Lockwood DNJ, van Brakel WH et al. Interventions for erythema nodosum leprosum. (Protocol) Cochrane Database Syst Rev, 2008; : CD006949.
31. Reinar LM, Forsetlund L, Bjorndal A, Lockwood D. Interventions for skin changes caused by nerve damage in leprosy. Cochrane Database Syst Rev, 2008; : CD004833.
32. World Health Organization. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser, 1998; 874: 1-43.
33. Lockwood D. Leprosy. Clin Evid, 2002; 8: 709-720.
34. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev, 2000; 71: 144-153.
35. Baohong J. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? Lepr Rev, 2001; 72: 3-7.
36. Lockwood DN, Kumar B. Treatment of leprosy. BMJ, 2004; 328(7454): 1447-1448.
37. Lockwood DN. Leprosy elimination-a virtual phenomenon or a reality? BMJ, 2002; 324(7352): 1516-1518.
38. ILEP. Report of the International Leprosy Association Technical Forum 2002. London; 2002.